Comparison · NCT03289351-2663e93b
2-drug Therapy vs 1-drug Therapy: Number of Participants With a Postoperative Readmission
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 2-drug Therapy vs 1-drug Therapy: Number of Participants With a Postoperative Readmission. Trial comparisons, record NCT03289351-2663e93b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03289351-2663e93b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.138 | 0.0785 | 0.23 | wilson | |
| Risk in group 2 | 0.0488 | 0.0191 | 0.119 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0887 | -0.00282 | 0.186 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.82 | 0.936 | 8.49 | log | |
| Odds ratio, group 1 over group 2 | 3.11 | 0.946 | 10.2 | log | |
| Number needed to treat, for one more participant with the outcome on 2-drug Therapy than on 1-drug Therapy | 11.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 2-drug Therapy | ceftriaxone/metronidazole | 11 | 80 | OG000 |
| Group 2 | 1-drug Therapy | piperacillin-tazobactam~Piperacillin, Tazobactam Drug Combination: Single drug therapy | 4 | 82 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Postoperative Readmission
- Description
- readmission within 30 days for any gastrointestinal complaints or infectious complications
- Time frame
- 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis
- NCT number
- NCT03289351
- Phases
- PHASE4
- Conditions
- Perforated Appendicitis, Postoperative Infection
- Interventions
- Piperacillin, Tazobactam Drug Combination
- Lead sponsor
- Phoenix Children's Hospital
- Results first posted
- 2024-01-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03289351?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03289351-2663e93b